-

Garuda Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Garuda Therapeutics (Garuda), a company creating off-the-shelf, blood stem cell therapies, today announced that Dhvanit Shah, Ph.D., Co-founder, President and Chief Executive Officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 at 9:30 am PT.

Garuda’s breakthrough platform and manufacturing technology for making Hematopoietic Stem Cells (gHSCs) offers the potential to provide curative, off-the-shelf treatments for patients around the world.

About Garuda Therapeutics

Garuda Therapeutics seeks to create a world that eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 120 diseases. https://garudatx.com/

Contacts

Media
MacDougall Advisors
Megan Prock McGrath
mmcgrath@macdougall.bio
(781) 235-3060

Garuda Therapeutics


Release Summary
Garuda Therapeutics announces a presentation at the 42nd Annual J.P. Morgan Healthcare Conference.
Release Versions

Contacts

Media
MacDougall Advisors
Megan Prock McGrath
mmcgrath@macdougall.bio
(781) 235-3060

More News From Garuda Therapeutics

Garuda Therapeutics Announces the Appointment of Panteli Theocharous, Ph.D., FRCPath as Chief Therapeutics Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Garuda Therapeutics announces the appointment of Panteli Theocharous, Ph.D., FRCPath as Chief Therapeutics Officer....

Garuda Therapeutics Announces the Appointment of Giorgia Scapin, Ph.D., as Chief Scientific Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Garuda Therapeutics announces the appointment of Giorgia Scapin, Ph.D., as Chief Scientific Officer....

Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Garuda Therapeutics (Garuda), a company creating off-the-shelf, durable blood stem cell-based cellular therapies, today announced a $62 million Series B financing led by Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management, and Aisling Capital, along with participation from Sectoral Asset Management, Mass General Brigham Ventures, Alexandria Venture Investments, and other elite investors and individuals. This brings the total amount of funding for...
Back to Newsroom